<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02137772</url>
  </required_header>
  <id_info>
    <org_study_id>8228-001</org_study_id>
    <secondary_id>2013-003831-31</secondary_id>
    <secondary_id>152923</secondary_id>
    <nct_id>NCT02137772</nct_id>
  </id_info>
  <brief_title>Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)</brief_title>
  <official_title>A Phase III Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-8228 (Letermovir) for the Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluated the efficacy and safety of letermovir (MK-8228) for the prevention of
      clinically-significant CMV infection in adult, CMV-seropositive recipients of allogeneic
      hematopoietic stem cell transplant (HSCT). The hypothesis being tested was that MK-8228 is
      superior to placebo in the prevention of clinically-significant CMV infection through Week 24
      post-transplant.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 6, 2014</start_date>
  <completion_date type="Actual">November 21, 2016</completion_date>
  <primary_completion_date type="Actual">August 8, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Clinically-significant CMV Infection up to Week 24 Post-transplant</measure>
    <time_frame>Up to Week 24 post-transplant</time_frame>
    <description>Clinically-significant CMV infection was defined as either one of the following: 1) onset of CMV end-organ disease, or 2) initiation of anti-CMV pre-emptive therapy based on documented CMV viremia and the clinical condition of the participant. The percentage of participants with clinically-significant CMV infection was assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Clinically-significant CMV Infection (Kaplan-Meier Estimate of Percentage of Participants With a Qualifying Event at Week 24 Post-transplant)</measure>
    <time_frame>Up to Week 24 post-transplant</time_frame>
    <description>Clinically-significant CMV infection was defined as either one of the following: 1) onset of CMV end-organ disease, or 2) initiation of anti-CMV pre-emptive therapy based on documented CMV viremia and the clinical condition of the participant. Time to onset of clinically-significant CMV infection was defined from the day of transplantation to the day the participant developed clinically-significant CMV infection, and was analyzed by the Kaplan-Meier method. Participants were censored at the last assessment for participants who discontinued or did not develop clinically-significant CMV infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinically-significant CMV Infection up to Week 14 Post-transplant</measure>
    <time_frame>Up to Week 14 post-transplant</time_frame>
    <description>Clinically-significant CMV infection was defined as either one of the following: 1) onset of CMV end-organ disease, or 2) initiation of anti-CMV pre-emptive therapy based on documented CMV viremia and the clinical condition of the participant. The percentage of participants with clinically-significant CMV infection was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With CMV End-organ Disease up to Week 24 Post-transplant</measure>
    <time_frame>Up to Week 24 post-transplant</time_frame>
    <description>CMV end-organ disease met per-protocol diagnostic criteria for CMV-pneumonia, gastrointestinal disease, hepatitis, central nervous system disease, retinitis, nephritis, cystitis, myocarditis, pancreatitis, or other disease categories. Only Clinical Adjudication Committee-confirmed CMV end-organ disease was included in this analysis. The percentage of participants with CMV end-organ disease was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With CMV End-organ Disease up to Week 14 Post-transplant</measure>
    <time_frame>Up to Week 14 post-transplant</time_frame>
    <description>CMV end-organ disease met per-protocol diagnostic criteria for CMV-pneumonia, gastrointestinal disease, hepatitis, central nervous system disease, retinitis, nephritis, cystitis, myocarditis, pancreatitis, or other disease categories. Only Clinical Adjudication Committee-confirmed CMV end-organ disease was included in this analysis. The percentage of participants with CMV end-organ disease was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Pre-emptive Therapy for CMV Viremia up to Week 14 Post-transplant</measure>
    <time_frame>Up to Week 14 post-transplant</time_frame>
    <description>Initiation of anti-CMV pre-emptive therapy was based on documented CMV viremia and the clinical condition of the participant. The percentage of participants with initiation of anti-CMV pre-emptive anti-CMV therapy was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Pre-emptive Therapy for CMV Viremia up to Week 24 Post-transplant</measure>
    <time_frame>Up to Week 24 post-transplant</time_frame>
    <description>Initiation of anti-CMV pre-emptive therapy was based on documented CMV viremia and the clinical condition of the participant. The percentage of participants with initiation of anti-CMV pre-emptive anti-CMV therapy was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Initiation of Pre-emptive Therapy for CMV Viremia (Kaplan-Meier Estimate of Percentage of Participants With a Qualifying Event at Week 24 Post-transplant)</measure>
    <time_frame>Up to Week 24 post-transplant</time_frame>
    <description>The need for anti-CMV pre-emptive therapy was based on documented CMV viremia and the clinical condition of the participant. The outcome was calculated from the day of transplantation to the start of anti-CMV pre-emptive therapy, and was analyzed by the Kaplan-Meier method. Participants were censored at the last assessment for participants who discontinued or did not initiate pre-emptive therapy.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of Participants With One or More Adverse Events up to Week 48 Post-transplant</measure>
    <time_frame>Up to Week 48 post-transplant</time_frame>
    <description>An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants Discontinued From Study Medication Due to an Adverse Event</measure>
    <time_frame>Up to Week 14 post-transplant</time_frame>
    <description>An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">570</enrollment>
  <condition>Prevention of CMV Infection or Disease</condition>
  <arm_group>
    <arm_group_label>Letermovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Letermovir oral or intravenous (IV) formulation was administered once daily for up to 14 weeks, beginning up to Day 28 days post-transplant. The dose was 240 mg once daily for participants receiving concomitant cyclosporin A and 480 mg once daily for participants not receiving cyclosporin A. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral or IV formulation was administered once daily for up to 14 weeks, beginning up to Day 28 post-transplant. The number of placebo tablets was to mimic that for letermovir administration according to the concomitant cyclosporin A status. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letermovir</intervention_name>
    <description>Letermovir 240 mg / 480 mg tablets, or 240 mg / 480 mg intravenous solution in 250 mL to be infused over 60 minutes.</description>
    <arm_group_label>Letermovir</arm_group_label>
    <other_name>MK-8228</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets, or intravenous solution in 250 mL to be infused over 60 minutes.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has documented seropositivity for CMV within 1 year before hematopoietic stem cell
             transplant (HSCT)

          -  Receiving first allogeneic HSCT (bone marrow, peripheral blood stem cell, or cord
             blood transplant)

          -  Female or male participant who is not of reproductive potential, or, if of
             reproductive potential, agrees to true abstinence or to use (or have their partner
             use) 2 acceptable methods of birth control from the time of consent through 90 days
             after the last dose of study drug

          -  Able to read, understand, and complete questionnaires and diaries

        Exclusion Criteria:

          -  Received a previous allogeneic HSCT (previous autologous HSCT is acceptable)

          -  History of CMV end-organ disease within 6 months before randomization

          -  Has evidence of CMV viremia (if tested) at any time from either signing of the
             Informed Consent Form or the HSCT procedure, whichever is earlier, until the time of
             randomization.

          -  Received the following within 7 days before screening or plans to receive during the
             study: ganciclovir, valganciclovir, foscarnet, acyclovir, valacyclovir, or famciclovir

          -  Received the following within 30 days before screening or plan to receive during the
             study: cidofovir, CMV hyper-immune globulin, any investigational CMV antiviral agent
             or biological therapy

          -  Has suspected or known hypersensitivity to ingredients of MK-8228 (letermovir)
             formulations

          -  Has severe hepatic insufficiency within 5 days before randomization

          -  Has end-stage renal impairment

          -  Has an uncontrolled infection on the day of randomization

          -  Requires mechanical ventilation or is hemodynamically unstable at the time of
             randomization

          -  Has documented positive results for human immunodeficiency virus (HIV) antibody,
             hepatitis C virus (HCV) antibody with detectable HCV ribonucleic acid, or hepatitis B
             surface antigen (HBsAg) within 90 days before randomization

          -  Has active solid tumor malignancies with the exception of localized basal cell or
             squamous cell skin cancer or the condition under treatment (for example, lymphoma)

          -  Is pregnant or expecting to conceive, is breastfeeding, or plans to breastfeed from
             the time of consent through 90 days after the last dose of study drug

          -  Is expecting to donate eggs or sperm from the time of consent through 90 days after
             the last dose of study drug

          -  Has participated in a study with an unapproved investigational compound (monoclonal
             antibodies are excepted) or device within 28 days of the first dose of study drug

          -  Has previously participated in a MK-8228 (letermovir) study

          -  Has, is, or is planning (during the study) to participate in any study involving
             administration of a CMV vaccine or another CMV investigational agent

          -  Is a user of recreational or illicit drugs or has a recent history (&lt;=1 year) of drug
             or alcohol abuse or dependence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>New Zealand</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2014</study_first_submitted>
  <study_first_submitted_qc>May 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2014</study_first_posted>
  <results_first_submitted>October 16, 2017</results_first_submitted>
  <results_first_submitted_qc>October 16, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 17, 2017</results_first_posted>
  <last_update_submitted>November 16, 2017</last_update_submitted>
  <last_update_submitted_qc>November 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 738 participants were screened, 570 were randomized 2:1 letermovir:placebo, and 565 received at least one dose of study medication.</recruitment_details>
      <pre_assignment_details>Screening could occur up to 15 days before Hematopoietic Stem Cell Transplant (HSCT) and no more than Day 28 post-transplant. From the time of screening to randomization, participants were tested weekly for Cytomegalovirus (CMV) viremia; a positive test resulted in exclusion from the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Letermovir</title>
          <description>Letermovir oral or intravenous (IV) formulation was administered once daily for up to 14 weeks, beginning up to Day 28 post-transplant. The dose was 240 mg once daily for participants receiving concomitant cyclosporin A and 480 mg once daily for participants not receiving cyclosporin A. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo oral or IV formulation was administered once daily for up to 14 weeks, beginning up to Day 28 post-transplant. The number of placebo tablets was to mimic that for letermovir administration according to the concomitant cyclosporin A status. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="376">Randomized participants</participants>
                <participants group_id="P2" count="194">Randomized participants</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated Participants</title>
              <participants_list>
                <participants group_id="P1" count="373"/>
                <participants group_id="P2" count="192"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="244"/>
                <participants group_id="P2" count="119"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="132"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized participants</population>
      <group_list>
        <group group_id="B1">
          <title>Letermovir</title>
          <description>Letermovir oral or intravenous (IV) formulation was administered once daily for up to 14 weeks, beginning up to Day 28 post-transplant. The dose was 240 mg once daily for participants receiving concomitant cyclosporin A and 480 mg once daily for participants not receiving cyclosporin A. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo oral or IV formulation was administered once daily for up to 14 weeks, beginning up to Day 28 post-transplant. The number of placebo tablets was to mimic that for letermovir administration according to the concomitant cyclosporin A status. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="376"/>
            <count group_id="B2" value="194"/>
            <count group_id="B3" value="570"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.8" spread="13.4"/>
                    <measurement group_id="B2" value="50.8" spread="14.8"/>
                    <measurement group_id="B3" value="50.8" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="162"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="239"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="214"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Risk Stratum for CMV Reactivation</title>
          <description>High risk: Participants meeting one or more of the following criteria at randomization: 1) Human leukocyte antigen (HLA)-related (sibling) donor with at least one mismatch at an HLA-A, -B or -DR gene loci 2) Haploidentical donor, 3) Unrelated donor with at least one mismatch at HLA- HLA-A, -B, -C or -DRB1 gene loci 4) Use of umbilical cord blood as stem cell source, 5) Use of ex vivo T-cell-depleted grafts, 6) Grade 2 or greater graft-versus-host disease requiring the use of systemic corticosteroids. Low risk: All other participants</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>High risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="254"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Clinically-significant CMV Infection up to Week 24 Post-transplant</title>
        <description>Clinically-significant CMV infection was defined as either one of the following: 1) onset of CMV end-organ disease, or 2) initiation of anti-CMV pre-emptive therapy based on documented CMV viremia and the clinical condition of the participant. The percentage of participants with clinically-significant CMV infection was assessed.</description>
        <time_frame>Up to Week 24 post-transplant</time_frame>
        <population>The Full Analysis Set (FAS) was all randomized participants who received ≥1 dose of study drug and had no detectable CMV DNA on Day 1 (randomization). Participants who prematurely discontinued or had a missing outcome through the 24-week visit window were considered treatment failure (i.e. Non-completers equal failure [NC=F] approach was used).</population>
        <group_list>
          <group group_id="O1">
            <title>Letermovir</title>
            <description>Letermovir oral or intravenous (IV) formulation was administered once daily for up to 14 weeks, beginning up to Day 28 post-transplant. The dose was 240 mg once daily for participants receiving concomitant cyclosporin A and 480 mg once daily for participants not receiving cyclosporin A. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo oral or IV formulation was administered once daily for up to 14 weeks, beginning up to Day 28 post-transplant. The number of placebo tablets was to mimic that for letermovir administration according to the concomitant cyclosporin A status. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinically-significant CMV Infection up to Week 24 Post-transplant</title>
          <description>Clinically-significant CMV infection was defined as either one of the following: 1) onset of CMV end-organ disease, or 2) initiation of anti-CMV pre-emptive therapy based on documented CMV viremia and the clinical condition of the participant. The percentage of participants with clinically-significant CMV infection was assessed.</description>
          <population>The Full Analysis Set (FAS) was all randomized participants who received ≥1 dose of study drug and had no detectable CMV DNA on Day 1 (randomization). Participants who prematurely discontinued or had a missing outcome through the 24-week visit window were considered treatment failure (i.e. Non-completers equal failure [NC=F] approach was used).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="325"/>
                <count group_id="O2" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5"/>
                    <measurement group_id="O2" value="60.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A 1-sided p-value ≤0.0249 for the risk difference was used for declaring statistical significance</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>The Mantel Haenszel analysis was adjusted for sample size for each stratum (high or low risk for CMV reactivation)</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-23.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.5</ci_lower_limit>
            <ci_upper_limit>-14.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of Clinically-significant CMV Infection (Kaplan-Meier Estimate of Percentage of Participants With a Qualifying Event at Week 24 Post-transplant)</title>
        <description>Clinically-significant CMV infection was defined as either one of the following: 1) onset of CMV end-organ disease, or 2) initiation of anti-CMV pre-emptive therapy based on documented CMV viremia and the clinical condition of the participant. Time to onset of clinically-significant CMV infection was defined from the day of transplantation to the day the participant developed clinically-significant CMV infection, and was analyzed by the Kaplan-Meier method. Participants were censored at the last assessment for participants who discontinued or did not develop clinically-significant CMV infection.</description>
        <time_frame>Up to Week 24 post-transplant</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had no detectable CMV viral DNA on the day treatment was initiated.</population>
        <group_list>
          <group group_id="O1">
            <title>Letermovir</title>
            <description>Letermovir oral or intravenous (IV) formulation was administered once daily for up to 14 weeks, beginning up to Day 28 post-transplant. The dose was 240 mg once daily for participants receiving concomitant cyclosporin A and 480 mg once daily for participants not receiving cyclosporin A. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo oral or IV formulation was administered once daily for up to 14 weeks, beginning up to Day 28 post-transplant. The number of placebo tablets was to mimic that for letermovir administration according to the concomitant cyclosporin A status. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of Clinically-significant CMV Infection (Kaplan-Meier Estimate of Percentage of Participants With a Qualifying Event at Week 24 Post-transplant)</title>
          <description>Clinically-significant CMV infection was defined as either one of the following: 1) onset of CMV end-organ disease, or 2) initiation of anti-CMV pre-emptive therapy based on documented CMV viremia and the clinical condition of the participant. Time to onset of clinically-significant CMV infection was defined from the day of transplantation to the day the participant developed clinically-significant CMV infection, and was analyzed by the Kaplan-Meier method. Participants were censored at the last assessment for participants who discontinued or did not develop clinically-significant CMV infection.</description>
          <population>All randomized participants who received at least one dose of study drug and had no detectable CMV viral DNA on the day treatment was initiated.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="325"/>
                <count group_id="O2" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9" lower_limit="14.4" upper_limit="23.5"/>
                    <measurement group_id="O2" value="44.3" lower_limit="36.4" upper_limit="52.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Nominal 2-sided p-value</p_value_desc>
            <method>Log Rank</method>
            <method_desc>The log rank test was adjusted for sample size for each stratum (high or low risk for CMV reactivation)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinically-significant CMV Infection up to Week 14 Post-transplant</title>
        <description>Clinically-significant CMV infection was defined as either one of the following: 1) onset of CMV end-organ disease, or 2) initiation of anti-CMV pre-emptive therapy based on documented CMV viremia and the clinical condition of the participant. The percentage of participants with clinically-significant CMV infection was assessed.</description>
        <time_frame>Up to Week 14 post-transplant</time_frame>
        <population>The FAS was all randomized participants who received ≥1 dose of study drug and had no detectable CMV DNA on Day 1. Participants who prematurely discontinued or had a missing outcome through the 14-week visit window were considered treatment failure (i.e. NC=F approach was used).</population>
        <group_list>
          <group group_id="O1">
            <title>Letermovir</title>
            <description>Letermovir oral or intravenous (IV) formulation was administered once daily for up to 14 weeks, beginning up to Day 28 post-transplant. The dose was 240 mg once daily for participants receiving concomitant cyclosporin A and 480 mg once daily for participants not receiving cyclosporin A. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo oral or IV formulation was administered once daily for up to 14 weeks, beginning up to Day 28 post-transplant. The number of placebo tablets was to mimic that for letermovir administration according to the concomitant cyclosporin A status. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinically-significant CMV Infection up to Week 14 Post-transplant</title>
          <description>Clinically-significant CMV infection was defined as either one of the following: 1) onset of CMV end-organ disease, or 2) initiation of anti-CMV pre-emptive therapy based on documented CMV viremia and the clinical condition of the participant. The percentage of participants with clinically-significant CMV infection was assessed.</description>
          <population>The FAS was all randomized participants who received ≥1 dose of study drug and had no detectable CMV DNA on Day 1. Participants who prematurely discontinued or had a missing outcome through the 14-week visit window were considered treatment failure (i.e. NC=F approach was used).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="325"/>
                <count group_id="O2" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.1"/>
                    <measurement group_id="O2" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Nominal 1-sided p-value</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>The Mantel Haenszel analysis was adjusted for sample size for each stratum (high or low risk for CMV reactivation)</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-31.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.9</ci_lower_limit>
            <ci_upper_limit>-22.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With CMV End-organ Disease up to Week 24 Post-transplant</title>
        <description>CMV end-organ disease met per-protocol diagnostic criteria for CMV-pneumonia, gastrointestinal disease, hepatitis, central nervous system disease, retinitis, nephritis, cystitis, myocarditis, pancreatitis, or other disease categories. Only Clinical Adjudication Committee-confirmed CMV end-organ disease was included in this analysis. The percentage of participants with CMV end-organ disease was assessed.</description>
        <time_frame>Up to Week 24 post-transplant</time_frame>
        <population>The FAS was all randomized participants who received ≥1 dose of study drug and had no detectable CMV DNA on Day 1. A participant with a missing value up to Week 24 was excluded from the analysis (i.e., Data as observed [DAO] approach was used).</population>
        <group_list>
          <group group_id="O1">
            <title>Letermovir</title>
            <description>Letermovir oral or intravenous (IV) formulation was administered once daily for up to 14 weeks, beginning up to Day 28 post-transplant. The dose was 240 mg once daily for participants receiving concomitant cyclosporin A and 480 mg once daily for participants not receiving cyclosporin A. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo oral or IV formulation was administered once daily for up to 14 weeks, beginning up to Day 28 post-transplant. The number of placebo tablets was to mimic that for letermovir administration according to the concomitant cyclosporin A status. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With CMV End-organ Disease up to Week 24 Post-transplant</title>
          <description>CMV end-organ disease met per-protocol diagnostic criteria for CMV-pneumonia, gastrointestinal disease, hepatitis, central nervous system disease, retinitis, nephritis, cystitis, myocarditis, pancreatitis, or other disease categories. Only Clinical Adjudication Committee-confirmed CMV end-organ disease was included in this analysis. The percentage of participants with CMV end-organ disease was assessed.</description>
          <population>The FAS was all randomized participants who received ≥1 dose of study drug and had no detectable CMV DNA on Day 1. A participant with a missing value up to Week 24 was excluded from the analysis (i.e., Data as observed [DAO] approach was used).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="254"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4056</p_value>
            <p_value_desc>Nominal 1-sided p-value</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>The Mantel Haenszel analysis was adjusted for sample size for each stratum (high or low risk for CMV reactivation)</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.0</ci_lower_limit>
            <ci_upper_limit>3.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With CMV End-organ Disease up to Week 14 Post-transplant</title>
        <description>CMV end-organ disease met per-protocol diagnostic criteria for CMV-pneumonia, gastrointestinal disease, hepatitis, central nervous system disease, retinitis, nephritis, cystitis, myocarditis, pancreatitis, or other disease categories. Only Clinical Adjudication Committee-confirmed CMV end-organ disease was included in this analysis. The percentage of participants with CMV end-organ disease was assessed.</description>
        <time_frame>Up to Week 14 post-transplant</time_frame>
        <population>The FAS was all randomized participants who received ≥1 dose of study drug and had no detectable CMV DNA on Day 1. A participant with a missing value up to Week 14 was excluded from the analysis (i.e., Data as observed [DAO] approach was used).</population>
        <group_list>
          <group group_id="O1">
            <title>Letermovir</title>
            <description>Letermovir oral or intravenous (IV) formulation was administered once daily for up to 14 weeks, beginning up to Day 28 post-transplant. The dose was 240 mg once daily for participants receiving concomitant cyclosporin A and 480 mg once daily for participants not receiving cyclosporin A. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo oral or IV formulation was administered once daily for up to 14 weeks, beginning up to Day 28 post-transplant. The number of placebo tablets was to mimic that for letermovir administration according to the concomitant cyclosporin A status. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With CMV End-organ Disease up to Week 14 Post-transplant</title>
          <description>CMV end-organ disease met per-protocol diagnostic criteria for CMV-pneumonia, gastrointestinal disease, hepatitis, central nervous system disease, retinitis, nephritis, cystitis, myocarditis, pancreatitis, or other disease categories. Only Clinical Adjudication Committee-confirmed CMV end-organ disease was included in this analysis. The percentage of participants with CMV end-organ disease was assessed.</description>
          <population>The FAS was all randomized participants who received ≥1 dose of study drug and had no detectable CMV DNA on Day 1. A participant with a missing value up to Week 14 was excluded from the analysis (i.e., Data as observed [DAO] approach was used).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="285"/>
                <count group_id="O2" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2258</p_value>
            <p_value_desc>Nominal 1-sided p-value</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>The Mantel Haenszel analysis was adjusted for sample size for each stratum (high or low risk for CMV reactivation)</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.5</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Pre-emptive Therapy for CMV Viremia up to Week 14 Post-transplant</title>
        <description>Initiation of anti-CMV pre-emptive therapy was based on documented CMV viremia and the clinical condition of the participant. The percentage of participants with initiation of anti-CMV pre-emptive anti-CMV therapy was assessed.</description>
        <time_frame>Up to Week 14 post-transplant</time_frame>
        <population>The FAS was all randomized participants who received ≥1 dose of study drug and had no detectable CMV DNA on Day 1. Participants who prematurely discontinued or had a missing outcome through the 14-week visit window were considered treatment failure (i.e. NC=F approach was used).</population>
        <group_list>
          <group group_id="O1">
            <title>Letermovir</title>
            <description>Letermovir oral or intravenous (IV) formulation was administered once daily for up to 14 weeks, beginning up to Day 28 post-transplant. The dose was 240 mg once daily for participants receiving concomitant cyclosporin A and 480 mg once daily for participants not receiving cyclosporin A. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo oral or IV formulation was administered once daily for up to 14 weeks, beginning up to Day 28 post-transplant. The number of placebo tablets was to mimic that for letermovir administration according to the concomitant cyclosporin A status. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Pre-emptive Therapy for CMV Viremia up to Week 14 Post-transplant</title>
          <description>Initiation of anti-CMV pre-emptive therapy was based on documented CMV viremia and the clinical condition of the participant. The percentage of participants with initiation of anti-CMV pre-emptive anti-CMV therapy was assessed.</description>
          <population>The FAS was all randomized participants who received ≥1 dose of study drug and had no detectable CMV DNA on Day 1. Participants who prematurely discontinued or had a missing outcome through the 14-week visit window were considered treatment failure (i.e. NC=F approach was used).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="325"/>
                <count group_id="O2" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8"/>
                    <measurement group_id="O2" value="49.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Nominal 1-sided p-value</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>The Mantel Haenszel analysis was adjusted for sample size for each stratum (high or low risk for CMV reactivation)</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-31.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.6</ci_lower_limit>
            <ci_upper_limit>-22.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Pre-emptive Therapy for CMV Viremia up to Week 24 Post-transplant</title>
        <description>Initiation of anti-CMV pre-emptive therapy was based on documented CMV viremia and the clinical condition of the participant. The percentage of participants with initiation of anti-CMV pre-emptive anti-CMV therapy was assessed.</description>
        <time_frame>Up to Week 24 post-transplant</time_frame>
        <population>The FAS was all randomized participants who received ≥1 dose of study drug and had no detectable CMV DNA on Day 1. Participants who prematurely discontinued or had a missing outcome through the 24-week visit window were considered treatment failure (i.e. NC=F approach was used).</population>
        <group_list>
          <group group_id="O1">
            <title>Letermovir</title>
            <description>Letermovir oral or intravenous (IV) formulation was administered once daily for up to 14 weeks, beginning up to Day 28 post-transplant. The dose was 240 mg once daily for participants receiving concomitant cyclosporin A and 480 mg once daily for participants not receiving cyclosporin A. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo oral or IV formulation was administered once daily for up to 14 weeks, beginning up to Day 28 post-transplant. The number of placebo tablets was to mimic that for letermovir administration according to the concomitant cyclosporin A status. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Pre-emptive Therapy for CMV Viremia up to Week 24 Post-transplant</title>
          <description>Initiation of anti-CMV pre-emptive therapy was based on documented CMV viremia and the clinical condition of the participant. The percentage of participants with initiation of anti-CMV pre-emptive anti-CMV therapy was assessed.</description>
          <population>The FAS was all randomized participants who received ≥1 dose of study drug and had no detectable CMV DNA on Day 1. Participants who prematurely discontinued or had a missing outcome through the 24-week visit window were considered treatment failure (i.e. NC=F approach was used).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="325"/>
                <count group_id="O2" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.6"/>
                    <measurement group_id="O2" value="59.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Nominal 1-sided p-value</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>The Mantel Haenszel analysis was adjusted for sample size for each stratum (high or low risk for CMV reactivation)</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-23.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.3</ci_lower_limit>
            <ci_upper_limit>-14.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Initiation of Pre-emptive Therapy for CMV Viremia (Kaplan-Meier Estimate of Percentage of Participants With a Qualifying Event at Week 24 Post-transplant)</title>
        <description>The need for anti-CMV pre-emptive therapy was based on documented CMV viremia and the clinical condition of the participant. The outcome was calculated from the day of transplantation to the start of anti-CMV pre-emptive therapy, and was analyzed by the Kaplan-Meier method. Participants were censored at the last assessment for participants who discontinued or did not initiate pre-emptive therapy.</description>
        <time_frame>Up to Week 24 post-transplant</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had no detectable CMV viral DNA on the day treatment was initiated.</population>
        <group_list>
          <group group_id="O1">
            <title>Letermovir</title>
            <description>Letermovir oral or intravenous (IV) formulation was administered once daily for up to 14 weeks, beginning up to Day 28 post-transplant. The dose was 240 mg once daily for participants receiving concomitant cyclosporin A and 480 mg once daily for participants not receiving cyclosporin A. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo oral or IV formulation was administered once daily for up to 14 weeks, beginning up to Day 28 post-transplant. The number of placebo tablets was to mimic that for letermovir administration according to the concomitant cyclosporin A status. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Initiation of Pre-emptive Therapy for CMV Viremia (Kaplan-Meier Estimate of Percentage of Participants With a Qualifying Event at Week 24 Post-transplant)</title>
          <description>The need for anti-CMV pre-emptive therapy was based on documented CMV viremia and the clinical condition of the participant. The outcome was calculated from the day of transplantation to the start of anti-CMV pre-emptive therapy, and was analyzed by the Kaplan-Meier method. Participants were censored at the last assessment for participants who discontinued or did not initiate pre-emptive therapy.</description>
          <population>All randomized participants who received at least one dose of study drug and had no detectable CMV viral DNA on the day treatment was initiated.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="325"/>
                <count group_id="O2" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2" lower_limit="12.8" upper_limit="21.6"/>
                    <measurement group_id="O2" value="42.4" lower_limit="34.7" upper_limit="50.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Nominal 2-sided p-value</p_value_desc>
            <method>Log Rank</method>
            <method_desc>The log rank test analysis was adjusted for sample size for each stratum (high or low risk for CMV reactivation)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With One or More Adverse Events up to Week 48 Post-transplant</title>
        <description>An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor’s product, is also an adverse event.</description>
        <time_frame>Up to Week 48 post-transplant</time_frame>
        <population>All randomized participants who received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Letermovir</title>
            <description>Letermovir oral or intravenous (IV) formulation was administered once daily for up to 14 weeks, beginning up to Day 28 post-transplant. The dose was 240 mg once daily for participants receiving concomitant cyclosporin A and 480 mg once daily for participants not receiving cyclosporin A. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo oral or IV formulation was administered once daily for up to 14 weeks, beginning up to Day 28 post-transplant. The number of placebo tablets was to mimic that for letermovir administration according to the concomitant cyclosporin A status. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With One or More Adverse Events up to Week 48 Post-transplant</title>
          <description>An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor’s product, is also an adverse event.</description>
          <population>All randomized participants who received at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="373"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.4"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Discontinued From Study Medication Due to an Adverse Event</title>
        <description>An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor’s product, is also an adverse event.</description>
        <time_frame>Up to Week 14 post-transplant</time_frame>
        <population>All randomized participants who received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Letermovir</title>
            <description>Letermovir oral or intravenous (IV) formulation was administered once daily for up to 14 weeks, beginning up to Day 28 post-transplant. The dose was 240 mg once daily for participants receiving concomitant cyclosporin A and 480 mg once daily for participants not receiving cyclosporin A. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo oral or IV formulation was administered once daily for up to 14 weeks, beginning up to Day 28 post-transplant. The number of placebo tablets was to mimic that for letermovir administration according to the concomitant cyclosporin A status. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Discontinued From Study Medication Due to an Adverse Event</title>
          <description>An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor’s product, is also an adverse event.</description>
          <population>All randomized participants who received at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="373"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.6"/>
                    <measurement group_id="O2" value="51.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Week 48 post-transplant</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Letermovir</title>
          <description>Letermovir oral or intravenous (IV) formulation was administered once daily for up to 14 weeks, beginning up to Day 28 post-transplant. The dose was 240 mg once daily for participants receiving concomitant cyclosporin A and 480 mg once daily for participants not receiving cyclosporin A. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo oral or IV formulation was administered once daily for up to 14 weeks, beginning up to Day 28 post-transplant. The number of placebo tablets was to mimic that for letermovir administration according to the concomitant cyclosporin A status. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="202" subjects_at_risk="373"/>
                <counts group_id="E2" subjects_affected="115" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Agranulocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Aplastic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Autoimmune haemolytic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="373"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Immune thrombocytopenic purpura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Inappropriate antidiuretic hormone secretion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="373"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Stomatitis haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="373"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="373"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="373"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Venoocclusive liver disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="373"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Graft versus host disease</sub_title>
                <counts group_id="E1" events="49" subjects_affected="45" subjects_at_risk="373"/>
                <counts group_id="E2" events="31" subjects_affected="29" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Transplant rejection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Adenoviral haemorrhagic cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Aspergillus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>BK virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Cellulitis orbital</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Cerebral toxoplasmosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Clostridium bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Cystitis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="373"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus viraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Enterococcal bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Epstein-Barr viraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Epstein-Barr virus infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Fusarium infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Gastroenteritis adenovirus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Gastrointestinal candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Implant site cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Klebsiella infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Meningitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Meningoencephalitis herpetic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Meningoencephalitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Mucormycosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Parainfluenzae virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="373"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Pneumonia adenoviral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Pneumonia parainfluenzae viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Pseudomonas bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Retinitis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Rhinovirus infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="373"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="373"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="373"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Systemic candida</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Viraemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="373"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Viral haemorrhagic cystitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Allergic transfusion reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Comminuted fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Delayed engraftment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Transfusion-related acute lung injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Transplant failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="373"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Lactose intolerance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Tetany</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Fibromyalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Fracture pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute lymphocytic leukaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Acute lymphocytic leukaemia recurrent</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="373"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia recurrent</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="373"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Mantle cell lymphoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Mantle cell lymphoma recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Mycosis fungoides</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Mycosis fungoides recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="373"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Natural killer-cell leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma recurrent</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Post transplant lymphoproliferative disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Primary myelofibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Neurotoxicity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Posterior reversible encephalopathy syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Substance-induced psychotic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="373"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Cystitis haemorrhagic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="373"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Diffuse alveolar damage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Tonsillar disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Stevens-Johnson syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Venoocclusive disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="373"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="360" subjects_at_risk="373"/>
                <counts group_id="E2" subjects_affected="186" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="39" subjects_affected="24" subjects_at_risk="373"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="373"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="373"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="32" subjects_affected="27" subjects_at_risk="373"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="373"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="53" subjects_affected="49" subjects_at_risk="373"/>
                <counts group_id="E2" events="21" subjects_affected="19" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="30" subjects_affected="23" subjects_at_risk="373"/>
                <counts group_id="E2" events="20" subjects_affected="17" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="373"/>
                <counts group_id="E2" events="24" subjects_affected="22" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="139" subjects_affected="108" subjects_at_risk="373"/>
                <counts group_id="E2" events="64" subjects_affected="51" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="373"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="373"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="373"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="141" subjects_affected="106" subjects_at_risk="373"/>
                <counts group_id="E2" events="64" subjects_affected="53" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="25" subjects_affected="24" subjects_at_risk="373"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="93" subjects_affected="79" subjects_at_risk="373"/>
                <counts group_id="E2" events="40" subjects_affected="35" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="36" subjects_affected="29" subjects_at_risk="373"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="373"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="63" subjects_affected="55" subjects_at_risk="373"/>
                <counts group_id="E2" events="30" subjects_affected="26" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="47" subjects_affected="45" subjects_at_risk="373"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="74" subjects_affected="60" subjects_at_risk="373"/>
                <counts group_id="E2" events="27" subjects_affected="23" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="112" subjects_affected="85" subjects_at_risk="373"/>
                <counts group_id="E2" events="60" subjects_affected="50" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Graft versus host disease</sub_title>
                <counts group_id="E1" events="173" subjects_affected="147" subjects_at_risk="373"/>
                <counts group_id="E2" events="91" subjects_affected="74" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="21" subjects_at_risk="373"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" events="65" subjects_affected="55" subjects_at_risk="373"/>
                <counts group_id="E2" events="93" subjects_affected="77" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="22" subjects_affected="19" subjects_at_risk="373"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Viraemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="373"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="31" subjects_affected="26" subjects_at_risk="373"/>
                <counts group_id="E2" events="20" subjects_affected="17" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="24" subjects_affected="21" subjects_at_risk="373"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="43" subjects_affected="39" subjects_at_risk="373"/>
                <counts group_id="E2" events="17" subjects_affected="14" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="48" subjects_affected="43" subjects_at_risk="373"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="373"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="29" subjects_affected="28" subjects_at_risk="373"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="23" subjects_at_risk="373"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="373"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="23" subjects_at_risk="373"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="31" subjects_affected="30" subjects_at_risk="373"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="26" subjects_affected="24" subjects_at_risk="373"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="373"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="373"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="24" subjects_affected="20" subjects_at_risk="373"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="30" subjects_affected="29" subjects_at_risk="373"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="373"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="68" subjects_affected="58" subjects_at_risk="373"/>
                <counts group_id="E2" events="26" subjects_affected="24" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="30" subjects_affected="29" subjects_at_risk="373"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="373"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="37" subjects_affected="35" subjects_at_risk="373"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="37" subjects_affected="35" subjects_at_risk="373"/>
                <counts group_id="E2" events="25" subjects_affected="22" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="373"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="70" subjects_affected="62" subjects_at_risk="373"/>
                <counts group_id="E2" events="28" subjects_affected="27" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="38" subjects_affected="36" subjects_at_risk="373"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="29" subjects_affected="25" subjects_at_risk="373"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="34" subjects_affected="32" subjects_at_risk="373"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="373"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="32" subjects_affected="31" subjects_at_risk="373"/>
                <counts group_id="E2" events="19" subjects_affected="16" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="37" subjects_affected="34" subjects_at_risk="373"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="35" subjects_affected="31" subjects_at_risk="373"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="109" subjects_affected="90" subjects_at_risk="373"/>
                <counts group_id="E2" events="62" subjects_affected="51" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="38" subjects_affected="34" subjects_at_risk="373"/>
                <counts group_id="E2" events="24" subjects_affected="23" subjects_at_risk="192"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="373"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="192"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

